Abbott Laboratories (ABT.N)
TEL AVIV, June 23 - Mylan NV chief financial officer John Sheehan will arrive in Israel on Wednesday for a meeting with the head of the Tel Aviv Stock Exchange to discuss a possible listing of its shares if it succeeds in buying Perrigo Co, an industry source said.
- Israel's Teva Pharmaceutical Industries Ltd has raised its stake in Mylan N.V. to the 4.61 percent needed for it to legally challenge Mylan's rejection of Teva's hostile takeover offer under Dutch law.
- Mylan NV's largest stakeholder, Abbott Laboratories , said it would back Mylan's proposed acquisition of Perrigo Co Plc , potentially helping Mylan fend off interest from Teva Pharmaceutical Industries Ltd .
June 16 - Mylan NV's largest stakeholder, Abbott Laboratories, said it would back Mylan's proposed acquisition of Perrigo Co Plc, potentially helping Mylan fend off interest from Teva Pharmaceutical Industries Ltd .
May 26 - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy.
(The following statement was released by the rating agency) CHICAGO, May 18 (Fitch) Fitch Ratings has downgraded Abbott Laboratories' (Abbott) long-term Issuer Default Rating (IDR) by one notch to 'A' and revised the Rating Outlook to Stable from Negative. In addition, the company's short-term IDR has been affirmed at 'F1'. Abbott had $8.9 billion in outstanding debt at March 31, 2015. A full list of Fitch's ratings actions follows at the end of this release. KEY RATING DRIVERS -- Fitch exp
LONDON, May 13 - AstraZeneca is diving deeper into personalised healthcare with two projects that move the concept beyond cancer into respiratory disorders and heart disease.
May 5 - Generic drugmaker Mylan NV, at the center of a high-stakes, three-way takeover battle, on Tuesday reported slightly higher-than-expected first-quarter profit and said it was "steadfast" in its commitment to acquire Ireland-based Perrigo Co.
- Abbott Laboratories on Wednesday said its initial proceeds of $5.3 billion from the recent sale to Mylan of part of its generic drug business were now worth more than $7 billion because of appreciation of the stock it obtained in the deal.
April 22 - Abbott Laboratories on Wednesday said its initial proceeds of $5.3 billion from the recent sale to Mylan of part of its generic drug business were now worth more than $7 billion because of appreciation of the stock it obtained in the deal.
|Johnson & Johnson (JNJ.N)||$98.11||-0.33|
|Pfizer Inc. (PFE.N)||$33.33||-0.04|
|Novartis AG (NOVN.VX)||CHF92.95||-0.10|
|Merck & Co., Inc. (MRK.N)||$57.36||-0.31|
|Sanofi SA (SASY.PA)||€87.16||-1.02|
|AstraZeneca plc (AZN.L)||4,149.00p||-18.00|
|GlaxoSmithKline plc (GSK.L)||1,342.00p||-5.50|
|Eli Lilly and Co (LLY.N)||$86.11||-0.03|
|Amgen, Inc. (AMGN.OQ)||$155.04||+1.78|
|Boston Scientific Corporation (BSX.N)||$17.58||+0.01|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Provider: Wright Reports
Provider: ValuEngine, Inc.
Trading Report for (ABT). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
Provider: New Constructs, LLC
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.